EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

Protocol of a drug–drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV

Ashley Lacombe-Duncan iD, Alice Tseng iD, Kimberly K Scarsi iD, Tessa Senneker iD, Hadas Kluger, Yasmeen Persad, Angela Underhill iD, V Logan Kennedy, Ian Armstrong, Raymond Fung, Amy Bourns, Quang Nguyen und 10 weitere

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16162 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Ashley Lacombe-Duncan und 21 weiteren Autor:innen. Beteiligte Einrichtung: Women's College Hospital, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Drug Interactions, HIV Infections, Emtricitabine, Tenofovir. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIMH NIH HHS, Gilead Sciences Inc., CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Trans/transfeminine women are disproportionally affected by HIV. Concerns regarding negative drug–drug interactions (DDIs) between ART drugs and gender‐affirming hormone therapy (GAHT), specifically feminizing hormone therapy (FHT), may contribute to the lower ART uptake by trans women with HIV compared with their cis counterparts. The aim of this study is to investigate the bidirectional pharmacokinetic effects of components of FHT regimens (oral oestradiol and androgen‐suppressing medications) with the ART regimen (bictegravir/emtricitabine/tenofovir alafenamide [B/F/TAF)].

Methods

We present a protocol for a three‐armed, parallel‐group, longitudinal (6‐month), DDI study. Group 1 includes 15 3trans women with HIV taking FHT and ART; group 2 includes 15 premenopausal cis women with HIV taking ART; group 3 includes 15 trans women without HIV taking FHT. Women with HIV must be on or switch to B/F/TAF at baseline and be virally suppressed for ≥3 months. Trans women must be taking a stable regimen of ≥2 mg daily oral oestradiol and an anti‐androgen (pharmaceutical, and/or surgical, and/or medical) for ≥3 months. Plasma ART drug concentrations will be sampled at Month 2 and compared between groups 1 and 2. Serum oestradiol concentrations will be sampled at baseline and Month 2 visits and compared between groups 1 and 3. The primary outcomes are B/F/TAF pharmacokinetic parameters ( C min , C max and AUC) and oestradiol concentrations ( C min , C 4h, C max and AUC) at month 2.

Discussion

This study is of global importance as it provides critical information regarding safe coadministration of B/F/TAF and FHT, both of which are life‐saving therapies for trans women with HIV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug InteractionsHIV InfectionsEmtricitabineTenofovirAnti-HIV AgentsEstradiolPiperazinesTransgender PersonsAdenineHumansFemaleAdultHeterocyclic Compounds, 4 or More RingsAlaninePyridonesLongitudinal StudiesDrug CombinationsAndrogen AntagonistsHeterocyclic Compounds, 3-RingMiddle AgedYoung AdultAmidesMale

Stichwörter der Autor:innen

HIVanti‐agentsdrug interactionsfeminizing hormonestransgender women

Substanzen

EmtricitabineTenofovirAnti-HIV AgentsEstradiolPiperazinesAdenineHeterocyclic Compounds, 4 or More RingsAlaninePyridonesDrug Combinations

Autor:innen und Institutionen

  • Women's College Hospital, Toronto, Ontario, Canada.
  • School of Social Work, University of Michigan, Ann Arbor, Michigan, USA.
  • Toronto General Hospital, Unity Health Network, Toronto, Ontario, Canada.
  • Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
  • University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Kingston Health Sciences Centre, Kingston, Ontario, Canada.

ORCID-Profile: Ashley Lacombe-Duncan, Alice Tseng, Kimberly K Scarsi, Tessa Senneker, Angela Underhill

Förderung

  • NIMH NIH HHS
  • Gilead Sciences Inc.
  • CIHR
  • Canadian Institutes of Health Research
  • Gilead Sciences

Zitieren

APA

Lacombe-Duncan, A., Tseng, A., Scarsi, K. K., Senneker, T., Kluger, H., Persad, Y., Underhill, A., Kennedy, V. L., Armstrong, I., Fung, R., Bourns, A., Nguyen, Q., Hranilovic, S., Weisdorf, T., Chan, L., Kia, H., Halpenny, R., Iyer, H., Jeyarajah, N., …, & Loutfy, M. (2024). Protocol of a drug–drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16162

Vancouver

Lacombe-Duncan A, Tseng A, Scarsi KK, Senneker T, Kluger H, Persad Y, et al. Protocol of a drug–drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16162

BibTeX
@article{LacombeDuncan2024,
  author = {Lacombe-Duncan, Ashley and Tseng, Alice and Scarsi, Kimberly K and Senneker, Tessa and Kluger, Hadas and Persad, Yasmeen and Underhill, Angela and Kennedy, V Logan and Armstrong, Ian and Fung, Raymond and Bourns, Amy and Nguyen, Quang and Hranilovic, Susan and Weisdorf, Thea and Chan, Louie and Kia, Hannah and Halpenny, Roberta and Iyer, Harshita and Jeyarajah, Nirubini and Kovchazov, George and Tharao, Wangari and Loutfy, Mona},
  title = {Protocol of a drug–drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16162}
}
Kostenlos starten →